Status: Not yet recruiting
A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002
The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are: Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002 . Participants will: Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of their symptoms
Participants needed: 143
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou MacroLink Biopharmaceutical LLCUpdated: Jul 27, 2026
Eligibility criteria
18 years of age and over, male or female, able to understand and willing to sign... [+5]
Pregnant or nursing females.Participants who have received chemotherapy, investi... [+6]